TIDMHCM
RNS Number : 0015L
Hutchison China Meditech Limited
27 April 2020
Results of Annual General Meeting
London: Monday, April 27, 2020: Hutchison China MediTech Limited
("Chi-Med") (Nasdaq/AIM: HCM) today announces that all ordinary
resolutions and special resolutions put to its Annual General
Meeting ("AGM") held on April 27, 2020 were duly passed. The poll
results of the resolutions were as follows:
Number of Votes (%)*
Resolutions For Against Withheld(#)
To consider and adopt the audited
financial statements and the reports
of the directors and independent
auditor for the year ended 31 December
1 2019. 622,475,006 135,425 209,095
(99.97825%) (0.02175%)
2(A) To re-elect Mr Simon To as a director. 547,656,413 36,229,215 38,935,898
(93.79515%) (6.20485%)
To re-elect Mr Christian Hogg as
2(B) a director. 614,200,226 8,605,840 15,460
(98.61822%) (1.38178%)
To re-elect Mr Johnny Cheng as a
2(C) director. 612,394,636 10,412,825 14,065
(98.32808%) (1.67192%)
2(D) To re-elect Dr Weiguo Su as a director. 612,400,256 10,410,325 10,945
(98.32849%) (1.67151%)
2(E) To re-elect Dr Dan Eldar as a director. 612,014,066 10,796,615 10,845
(98.26647%) (1.73353%)
2(F) To re-elect Ms Edith Shih as a director. 612,006,786 10,798,775 15,965
(98.26611%) (1.73389%)
To re-elect Mr Paul Carter as a
2(G) director. 620,440,741 2,367,325 13,460
(99.61989%) (0.38011%)
To re-elect Dr Karen Ferrante as
2(H) a director. 622,577,316 233,365 10,845
(99.96253%) (0.03747%)
To re-elect Mr Graeme Jack as a
2(I) director. 619,884,406 2,921,135 15,985
(99.53097%) (0.46903%)
To re-elect Professor Tony Mok as
2(J) a director. 622,805,231 5,450 10,845
(99.99912%) (0.00088%)
To re-appoint PricewaterhouseCoopers
as the auditor of the Company and
authorise the board of directors
3 to fix the auditor's remuneration. 622,682,786 125,795 12,945
(99.97980%) (0.02020%)
To grant a general
mandate to the
directors of the
Ordinary Resolution Company to issue
4 No. 4(A) : additional shares. 615,116,216 7,686,590 18,720
(98.76581%) (1.23419%)
To disapply pre-emption
Special Resolution rights (general
No. 4(B) : power). 618,134,451 4,656,435 30,640
(99.25233%) (0.74767%)
To disapply pre-emption
rights (in connection
Special Resolution with an equity
No. 4(C) : raise). 529,841,459 81,598,207 11,381,860
(86.65474%) (13.34526%)
To grant a general
mandate to the
directors of the
Company to repurchase
Ordinary Resolution shares of the
No. 4(D) : Company. 622,786,026 25,890 9,610
(99.99584%) (0.00416%)
To amend the 2015
Share Option Scheme
and refresh the
scheme mandate
limit under the
2015 Share Option
5. Ordinary Resolution : Scheme. 501,381,220 83,165,305 38,275,001
(85.77268%) (14.22732%)
To adopt a new
memorandum and
articles of association
6 Special Resolution : of the Company. 622,545,861 248,265 27,400
(99.96014%) (0.03986%)
* Percentages rounded to 5 decimal places
(#) A vote withheld is not a vote in law and is not counted in
the calculation of the proportion of the votes for and against a
resolution.
As at the date of the AGM, the number of issued shares of
Chi-Med was 690,574,765, which was the total number of shares
entitling the holders to attend and vote on the ordinary
resolutions and special resolutions proposed at the AGM.
About Chi-Med
Chi-Med (Nasdaq/AIM: HCM) is an innovative biopharmaceutical
company committed, over the past twenty years, to the discovery and
global development of targeted therapies and immunotherapies for
the treatment of cancer and immunological diseases. It has a
portfolio of eight cancer drug candidates currently in clinical
studies around the world and extensive commercial infrastructure in
its home market of China. For more information, please visit:
www.chi-med.com.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President +852 2121 8200
Annie Cheng, Vice President +1 (973) 567 3786
Media Enquiries
Americas - Brad Miles, Solebury Trout +1 (917) 570 7340 (Mobile)
bmiles@troutgroup.com
Europe - Ben Atwell / Alex Shaw, FTI Consulting +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779
545 055 (Mobile)
Chi-Med@fticonsulting.com
Asia - Joseph Chi Lo / Zhou Yi, Brunswick +852 9850 5033 (Mobile), jlo@brunswickgroup.com /
+852 97 83 6894 (Mobile), y zhou@brunswickgroup.com
Nominated Advisor
Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK)
Limited +44 (20) 7886 2500
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RAGSEEFEWESSEIL
(END) Dow Jones Newswires
April 27, 2020 09:00 ET (13:00 GMT)
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
